MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.300
-0.020 (-1.52%)
At close: Jun 22, 2026, 4:00 PM EDT
1.305
+0.005 (0.38%)
After-hours: Jun 22, 2026, 4:10 PM EDT
MediciNova Employees
MediciNova had 6 employees as of December 31, 2025. The number of employees decreased by 7 or -53.85% compared to the previous year.
Employees
6
Change (1Y)
-7
Growth (1Y)
-53.85%
Revenue / Employee
$99,440
Profits / Employee
-$1,953,349
Market Cap
63.99M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6 | -7 | -53.85% |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | 0 | - |
| Dec 31, 2022 | 13 | 2 | 18.18% |
| Dec 31, 2021 | 11 | 2 | 22.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Acrivon Therapeutics | 76 |
| Seres Therapeutics | 66 |
| PMV Pharmaceuticals | 54 |
| BeyondSpring | 44 |
| eXoZymes | 32 |
| iBio, Inc. | 20 |
| Edesa Biotech | 17 |
| ImageneBio | 17 |
MNOV News
- 14 days ago - MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment - GlobeNewsWire
- 27 days ago - MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewsWire
- 27 days ago - MediciNova Slides: Corporate presentation - Filings
- 5 weeks ago - MediciNova Quarterly report: Q1 2026 - Filings
- 7 weeks ago - MediciNova Proxy statement: Proxy filing - Filings
- 7 weeks ago - MediciNova Proxy statement: Proxy filing - Filings
- 2 months ago - MediciNova’s peer-reviewed ibudilast study advances clinical translation - TheFly
- 2 months ago - New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - GlobeNewsWire